Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells.
Bieback K., Schallmoser K., Klüter H., Strunk D.
Clinical Trial, published in Transfus Med Hemother (2008) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Transfus Med Hemother (2008)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 21512644
- PMCID
- PMC3076361
- DOI
- 10.1159/000141567
- Citations
- 60
Abstract (original English)
SUMMARY: Multipotent mesenchymal stromal cells (MSCs) are currently exploited in numerous clinical trials to investigate their potential in immune regulation, hematopoiesis, and tissue regeneration. The low frequency of MSCs necessitates cell expansion to achieve transplantable numbers. The challenge is to assure safe and high-quality cell production. GMP(Good Manufacturing Practice)-graded cell processing such as cell preparation, culture, and manipulation is mandatory for the progress of such advanced cell therapy. This review summarizes protocols to isolate MSCs from bone marrow and adipose tissue and to expand MSCs for clinical use focussing on culture media composition as well as culture devices and assays to ensure and control quality of the final product. Derzeit laufen viele klinische Studien mit multipotenten mesenchymalen Stromazellen (MSCs), um deren Potenzial bei der Immunregulation, Hämatopoese und Geweberegeneration zu untersuchen. Der geringe Gehalt an MSCs macht eine Zellexpansion erforderlich, um transplantierbare Mengen zu erhalten. Die Herausforderung dabei besteht in der Gewährleistung einer sicheren und hochwertigen Zellproduktion. Eine gestaffelte Zellprozessierung (Zellpräparation, -kultivierung und -manipulation), die auf GMP(Good Manufacturing Practice)-Prinzipien basiert, ist für die Weiterentwicklung dieser hoch entwickelten Zelltherapie zwingend erfo
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.